Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus
  • PFAS in Water
  • Tear Gas and ICE Raids

WHAT'S NEW

  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus
  • PFAS in Water
  • Tear Gas and ICE Raids

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Nov 21 2025

Full Issue

Viewpoints: Trump's Plan For GLP-1s Fails Most Americans; CDC Website Now Promotes Anti-Vaccine Ideology

Opinion writers discuss these public health issues.

Stat: Trump’s Regressive Deal On GLP-1s Misses The Mark For Patients Like Me

The U.S. government is finally flexing its negotiating muscle to reduce GLP-1 prices and expand access to these medicines — for weight loss — in federal health programs. President Trump’s much-anticipated “deal” with GLP-1 manufacturers Eli Lilly and Novo Nordisk makes modest steps to expand patient access to the class of GLP-1 medications for the many millions of Americans who struggle with obesity. (Gavin Hart, 11/21)

The Washington Post: RFK Jr. Contaminates CDC Website With Lies About Vaccines And Autism

On Wednesday, the Centers for Disease Control and Prevention updated its website to surrender its steadfast adherence to vaccine science. The links between immunizations and autism, the site now reads, “have been ignored by health authorities.” (11/20)

The New York Times: Our Depressing Vaccine Future Laid Bare On The C.D.C. Website

Kennedy has a rhetorical advantage in that his deceptions can be definitive while scientific honesty has to come with caveats. (Jessica Grose, 11/20)

Stat: FDA’s New Voucher Program Replaces Science With Barter 

The recent news that the head of the Food and Drug Administration’s drug reviewing division had been ousted showed a federal health administration in chaos. Yet a peek behind the main storyline reveals that something more troubling is happening. (Daniel Carpenter, Thomas Hwang and Aaron S. Kesselheim, 11/21)

St. Louis Post-Dispatch: Pharmacy Benefit Managers Keep Costs Down. Leave Them Alone.

For carpenters in Missouri, every dollar counts. Between taxes, insurance and the rising cost of materials, it seems like money doesn’t go as far as it used to — because it doesn’t. That’s why I don’t understand why some in the Missouri Legislature would even consider prohibitive legislation that would raise the cost of health care for workers all across the state from all different walks of life. (Mark Dalton, 11/20)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 7
  • Wednesday, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF